NCT07805954
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07805954
Title Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)
Acronym RASolute 309
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Revolution Medicines, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Arizona RECRUITING Phoenix Arizona 85054 United States Details
HonorHealth Research Institute RECRUITING Scottsdale Arizona 85258 United States Details
Mayo Clinic Florida RECRUITING Jacksonville Florida 32224 United States Details
Moffitt Cancer Center RECRUITING Tampa Florida 33612 United States Details
Mayo Clinic Rochester RECRUITING Rochester Minnesota 55905 United States Details
Rhode Island Hospital RECRUITING Providence Rhode Island 02903 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field